Surface functionalized nanoparticles of NVP an improved strategy to tackle deadly HIV infection

  • Bhagyashree R Dalvi
  • Shilpa M Velhal
  • Atmaram B Bandivadekar
  • Absar Ahmad
  • Padma V Devarajan
Open Access
ePoster presentation
  • 559 Downloads

Keywords

Nevirapine Surface Functionalization Entrapment Efficiency Uptake Study High Cell Viability 

Background

The therapeutic efficacy of nevirapine (NVP) is hampered by its poor solubility; poor ability to target infected cells and inherent toxicity. The objective of the present study was surface functionalization with a new targeting ligand to enable enhanced efficacy.

Methods

Surface functionalization of GMS nVP auNPs was studied by fluroscence spectrophotometry. Nanoformulations and NVP were evaluated for cytotoxicity at 1, 2 and 24 hours and uptake study at 0.5, 1 and 2 hours. In vitro anti-HIV activity was evaluated in TZM bl cell line against HeLa/LaV virus.

Results

GMS nVP auNPs with > 75% entrapment efficiency & < 300nm particle size were prepared and surface modified nanoparticles showed >85% binding to the ligand. In cytotoxicity study nanoformulations showed higher cell viability at all time points as compared to NVP. Cell uptake study revealed higher uptake of nanoparticles as compared to NVP only. In vitro anti HIV assay of surface modified revealed 10 fold increased activity as compared to NVP.

Conclusion

Nanosize and surface functionalization both play an important role in enhancing anti HIV potential of GMS nVP auNPs.

Copyright information

© Dalvi et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Bhagyashree R Dalvi
    • 1
  • Shilpa M Velhal
    • 2
  • Atmaram B Bandivadekar
    • 2
  • Absar Ahmad
    • 3
  • Padma V Devarajan
    • 1
  1. 1.Department of Pharmaceutical Sciences and TechnologyInstitute of Chemical TechnologyMumbaiIndia
  2. 2.National Institute for Research in Reproductive HealthMumbaiIndia
  3. 3.Biochemical Sciences, National Chemical Laboratory (CSIR)PuneIndia

Personalised recommendations